Answers are grounded in this paper and cite their sources.
TAS-117 is a highly potent and selective, oral, allosteric pan-AKT inhibitor under development for advanced/metastatic solid tumors. The safety, clinical pharmacology, pharmacogenomics and efficacy were investigated.
No takes yet. Share an insight, caveat, or question.
Doi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: